These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1271 related articles for article (PubMed ID: 8156501)

  • 21. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
    Radvanyi LG; Bernatchez C; Zhang M; Fox PS; Miller P; Chacon J; Wu R; Lizee G; Mahoney S; Alvarado G; Glass M; Johnson VE; McMannis JD; Shpall E; Prieto V; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Patel S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Davies MA; Mansaray R; Fulbright OJ; Toth C; Ramachandran R; Wardell S; Gonzalez A; Hwu P
    Clin Cancer Res; 2012 Dec; 18(24):6758-70. PubMed ID: 23032743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial.
    Dillman RO; Oldham RK; Barth NM; Cohen RJ; Minor DR; Birch R; Yannelli JR; Maleckar JR; Sferruzza A; Arnold J
    Cancer; 1991 Jul; 68(1):1-8. PubMed ID: 2049729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
    Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
    Friedman KM; Prieto PA; Devillier LE; Gross CA; Yang JC; Wunderlich JR; Rosenberg SA; Dudley ME
    J Immunother; 2012 Jun; 35(5):400-8. PubMed ID: 22576345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
    Dudley ME; Yang JC; Sherry R; Hughes MS; Royal R; Kammula U; Robbins PF; Huang J; Citrin DE; Leitman SF; Wunderlich J; Restifo NP; Thomasian A; Downey SG; Smith FO; Klapper J; Morton K; Laurencot C; White DE; Rosenberg SA
    J Clin Oncol; 2008 Nov; 26(32):5233-9. PubMed ID: 18809613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
    Merrouche Y; Negrier S; Bain C; Combaret V; Mercatello A; Coronel B; Moskovtchenko JF; Tolstoshev P; Moen R; Philip T
    J Clin Oncol; 1995 Feb; 13(2):410-8. PubMed ID: 7844602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancer.
    Dillman R; Schiltz P; DePriest C; Barth N; Beutel L; de Leon C; O'Connor A; Nayak S
    Cancer Biother Radiopharm; 2004 Dec; 19(6):730-7. PubMed ID: 15665620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.
    Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM
    J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.
    Besser MJ; Itzhaki O; Ben-Betzalel G; Zippel DB; Zikich D; Kubi A; Brezinger K; Nissani A; Levi M; Zeltzer LA; Ben-Nun A; Asher N; Shimoni A; Nagler A; Markel G; Shapira-Frommer R; Schachter J
    Mol Carcinog; 2020 Jul; 59(7):736-744. PubMed ID: 32250515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
    Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D
    J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy.
    Itzhaki O; Hovav E; Ziporen Y; Levy D; Kubi A; Zikich D; Hershkovitz L; Treves AJ; Shalmon B; Zippel D; Markel G; Shapira-Frommer R; Schachter J; Besser MJ
    J Immunother; 2011 Mar; 34(2):212-20. PubMed ID: 21304398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial.
    Khammari A; Nguyen JM; Leccia MT; Guillot B; Saiagh S; Pandolfino MC; Knol AC; Quéreux G; Chiffolettau A; Labarrière N; Dréno B
    Cancer Immunol Immunother; 2020 Aug; 69(8):1663-1672. PubMed ID: 32306076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
    Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
    J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
    Dafni U; Michielin O; Lluesma SM; Tsourti Z; Polydoropoulou V; Karlis D; Besser MJ; Haanen J; Svane IM; Ohashi PS; Kammula US; Orcurto A; Zimmermann S; Trueb L; Klebanoff CA; Lotze MT; Kandalaft LE; Coukos G
    Ann Oncol; 2019 Dec; 30(12):1902-1913. PubMed ID: 31566658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.
    Ben-Avi R; Itzhaki O; Simansky D; Zippel D; Markel G; Ben Nun A; Schachter J; Besser MJ
    J Immunother; 2016 Jun; 39(5):218-22. PubMed ID: 27163742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
    Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
    Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.
    Goff SL; Smith FO; Klapper JA; Sherry R; Wunderlich JR; Steinberg SM; White D; Rosenberg SA; Dudley ME; Yang JC
    J Immunother; 2010 Oct; 33(8):840-7. PubMed ID: 20842052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
    Dudley ME; Gross CA; Langhan MM; Garcia MR; Sherry RM; Yang JC; Phan GQ; Kammula US; Hughes MS; Citrin DE; Restifo NP; Wunderlich JR; Prieto PA; Hong JJ; Langan RC; Zlott DA; Morton KE; White DE; Laurencot CM; Rosenberg SA
    Clin Cancer Res; 2010 Dec; 16(24):6122-31. PubMed ID: 20668005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study.
    Aebersold P; Kasid A; Rosenberg SA
    Hum Gene Ther; 1990; 1(4):373-84. PubMed ID: 1964094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.